ResMed (RMD) Stock Price, News & Analysis

Company Overview

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders. The company also supplies ventilators and respiratory care solutions for use in both home and clinical settings. Complementing its hardware, ResMed offers cloud-based software platforms and patient engagement tools that enable remote monitoring, data analytics and care management for healthcare professionals and homecare providers.

ResMed serves a broad global market, including sleep clinics, hospitals, home healthcare providers and individual patients across North America, Europe, Asia-Pacific and other regions. The company emphasizes research and development, regulatory compliance and partnerships with healthcare stakeholders to expand access to diagnosis and long-term management of respiratory conditions.

ResMed is led by President and Chief Executive Officer Michael J. “Mick” Farrell and maintains a strategic focus on integrating digital health and connectivity with its device offerings to improve therapy adherence, enable remote care delivery and support value-based models for chronic respiratory disease management.

Key Stats

• Today's Range: $207.25 to $211.06
• 50-Day Range: $198.87 to $233.60
• 52-Week Range: $198.61 to $293.81
• Volume: 1.10 million shs
• Average Volume: 1.50 million shs
• Market Capitalization: $30.31 billion
• P/E Ratio: 20.06
• Dividend Yield: 1.15%
• Price Target: $286.18
• Consensus Rating: Moderate Buy

ResMed Stock Analysis - MarketRank™

ResMed scored higher than 96% of companies evaluated by MarketBeat, and ranked 20th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ResMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 9 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

ResMed has a consensus price target of $286.18, representing about 37.6% upside from its current price of $208.04.

Amount of Analyst Coverage

ResMed has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.81%

Earnings Growth

Earnings for ResMed are expected to grow by 8.81% in the coming year, from $11.13 to $12.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ResMed is 20.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of ResMed is 20.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.26.

Price to Earnings Growth Ratio

ResMed has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

ResMed has a P/B Ratio of 4.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.50% of the float of ResMed has been sold short.

Short Interest Ratio / Days to Cover

ResMed has a short interest ratio ("days to cover") of 10.28, which indicates bearish sentiment.

Change versus previous month

Short interest in ResMed has recently increased by 6.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

ResMed pays a meaningful dividend of 1.15%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

ResMed has been increasing its dividend for 13 years.

Dividend Coverage

The dividend payout ratio of ResMed is 23.14%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, ResMed will have a dividend payout ratio of 19.82% next year. This indicates that ResMed will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.84

News Sentiment

ResMed has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for ResMed this week, compared to 6 articles on an average week.

Search Interest

27 people have searched for RMD on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.

MarketBeat Follows

9 people have added ResMed to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,386,031.00 in company stock.

Percentage Held by Insiders

0.65% of the stock of ResMed is held by insiders.

Percentage Held by Institutions

54.98% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 3/19 Dividend: 2/12/2026
• Ex-Dividend for 3/19 Dividend: 2/12/2026
• Dividend Payable: 3/19/2026
• Last Earnings: 4/30/2026
• Record date for 6/18 Dividend: 5/14/2026
• Ex-Dividend for 6/18 Dividend: 5/14/2026
• Today: 5/24/2026
• 46th Annual William Blair Growth Stock Conference: 6/02/2026
• Dividend Payable: 6/18/2026
• Fiscal Year End: 6/30/2026
• Next Earnings (Estimated): 7/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:RMD
• CIK: 943819
• Web: www.resmed.com
• Phone: (858) 836-5000
• Fax: 858-836-5501
• Employees: 10,600
• Year Founded: 1994

Price Target and Rating

• Average Price Target for ResMed: $286.18
• High Price Target: $345.00
• Low Price Target: $225.00
• Potential Upside/Downside: +37.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.37
• Trailing P/E Ratio: 20.06
• Forward P/E Ratio: 18.69
• P/E Growth: 1.33
• Net Income: $1.40 billion
• Net Margins: 27.44%
• Pretax Margin: 34.37%
• Return on Equity: 25.35%
• Return on Assets: 18.69%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 3.01
• Quick Ratio: 2.33

Sales & Book Value

• Annual Sales: $5.15 billion
• Price / Sales: 5.89
• Cash Flow: $11.20 per share
• Price / Cash Flow: 18.57
• Book Value: $44.56 per share
• Price / Book: 4.67

Miscellaneous

• Outstanding Shares: 145,680,000
• Free Float: 144,731,000
• Market Cap: $30.31 billion
• Optionable: Optionable
• Beta: 0.84